UniProtKB/Swiss-Prot Q9NZM5: Variant p.Gln389Arg

Ribosome biogenesis protein NOP53
Gene: NOP53
Feedback?

Variant information Variant position:

389 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Glutamine (Q) to Arginine (R) at position 389 (Q389R, p.Gln389Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and polar (Q) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs1804994 [ dbSNP | Ensembl ]

Sequence information Variant position:

389 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

478 The length of the canonical sequence.
Location on the sequence:

FRLRGIKAQVALRLAELARR Q RRRQARREAEADKPRRLGRL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         FRLRGIKAQV--ALRLAELARRQRRRQARREAEADKPRRLG-RL

Mouse                         FRLRGIKAQV--ARRLAELARRREQRRIRRLAEADKPRRLG

Caenorhabditis elegans        YRTKQLHKEL-DEEEKQRHEESEVRKKEKLINKLTKRQQLG

Drosophila                    IRIKSIRHEL--DDEEEDLNDLKKRRKQRAEKAKFEPKRLG

Baker's yeast                 ------LEEVINSEETEILSAIESDSNKVKKSKKNKKHKLG

Fission yeast                 -KAPAISKKLQQKDKAEKFSNKAVSSSTTEI--KLKKKKFG

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 478	Ribosome biogenesis protein NOP53
Region	148 – 431	Mediates interaction with CDKN2A/isoform tumor suppressor ARF
Region	181 – 478	Mediates interaction with NF2
Region	347 – 395	Nucleolar localization signal

Literature citations
A transcript map of the chromosome 19q-Arm glioma tumor suppressor region.
Smith J.S.; Tachibana I.; Pohl U.; Lee H.K.; Thanarajasingam U.; Portier B.P.; Ueki K.; Billings S.; Ramaswamy S.; Mohrenweiser H.W.; Scheithauer B.W.; Louis D.N.; Jenkins R.B.;
Genomics 64:44-50(2000)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANT ARG-389; TISSUE SPECIFICITY; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]; VARIANT ARG-389; Submission
The European IMAGE consortium;
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 12-478; VARIANT ARG-389; The full-ORF clone resource of the German cDNA consortium.
Bechtel S.; Rosenfelder H.; Duda A.; Schmidt C.P.; Ernst U.; Wellenreuther R.; Mehrle A.; Schuster C.; Bahr A.; Bloecker H.; Heubner D.; Hoerlein A.; Michel G.; Wedler H.; Koehrer K.; Ottenwaelder B.; Poustka A.; Wiemann S.; Schupp I.;
BMC Genomics 8:399-399(2007)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 218-477; VARIANT ARG-389;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.